RNS - Operational Update part 226 Jun 2023 10:11
The team has also been managing the vegetative and flowering stages of cultivation in
order that harvesting work can be staggered efficiently over time. This minimises
operating costs and increases quality as the team can work steadily and consistently
rather than be rushed if a number of cultivars have to be harvested at the same time. This
is a key KPI for future commercial cultivation. The improvements in plant yield and health
are visibly noticeable when comparing 2022 trial plants with the current trial crops.
Research
RCTs (Randomised Controlled Trials) Using MRX1 Cannabidiol Based Medicaloil
The Company's patent pending MRX1 cannabidiol based medical oil formulation goes onto stability testing on 3 July, 2023, in preparation for being used in the CIPN (Chemotherapy Induced Peripheral Neuropathy) and endometriosis RCTs to be conducted by the University of Edinburgh. Stability testing is required to confirm the medicine's storage requirements and shelf life.
DJT Genetic Stabilisation
The genetics programme is part way through its second cycle with third generation seeds
being produced by some 57 plants. The total number of seed lines in the genetic stabilisation programme is 127 providing DJT with opportunities to develop specialist
genetics in the future. Since commencing the genetic breeding programme in February
2022:
1. The time from germination to seed production has decreased from an average of 95
days to an average of 35 days.
2. The number of seeds produced per plant has increased from 1-10 to approx. 300 seeds per plant. The highest yield to date is more than 1,000 seeds from one plant.
Exercise Of Options
Ananda has received gross funds of £18,812.50 from James Kerr for the exercise of 4,180,455 options at 0.45 pence per share (the "Option Shares"). 4,180,455 Ordinary Shares have been approved for issue to Mr Kerr.
Application for Admission
Application will be made for the Option Shares to be admitted to trading on the Access segment of the AQSE Growth Market. It is expected that admission will become effective on 30 June 2023.
The Option Shares will, on admission, rank pari passu in all respects with the Ordinary Shares in issue and will rank in full for all dividends and other distributions hereafter declared, paid or made on the ordinary share capital of the Company.
Total Voting Rights
Following the issue of the Option Shares, Ananda has 2,878,027,906 Ordinary Shares in issue, each share carrying the right to one vote.
This figure of 2,878,027,906 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
_____________________
Sign In
Follow the stocks
